ESCITALOPRAM OXALATE tablet

Country: United States

Language: English

Source: NLM (National Library of Medicine)

Buy It Now

Active ingredient:

ESCITALOPRAM OXALATE (UNII: 5U85DBW7LO) (ESCITALOPRAM - UNII:4O4S742ANY)

Available from:

Contract Pharmacy Services-PA

INN (International Name):

ESCITALOPRAM OXALATE

Composition:

ESCITALOPRAM 20 mg

Administration route:

ORAL

Prescription type:

PRESCRIPTION DRUG

Therapeutic indications:

Escitalopram tablets, USP are indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [ see Clinical Studies (14.1) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. Escitalopram tablets, USP are indicated for the acute treatment of Generalized Anxiety Disorder (GAD) in adults [ see   Clinical   Studies   (14.2) ]. Generalized Anxiety Disorder (DSM-IV) is characteriz

Product summary:

Escitalopram tablets, USP 20 mg are white to off-white, round, biconvex, film coated tablets debossed with break line on one side, separating '11' and '37' on one side, and '20' on other side. NDC 67046-174-07 blisterpacks of 7 NDC 67046-174-14 blisterpacks of 14 NDC 67046-174-15 blisterpacks of 15 NDC 67046-174-20 blisterpacks of 20 NDC 67046-174-21 blisterpacks of 21 NDC 67046-174-28 blisterpacks of 28 NDC 67046-174-30 blisterpacks of 30 NDC 67046-174-60 blisterpacks of 60 Storage and Handling Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Authorization status:

Abbreviated New Drug Application

Patient Information leaflet

                                ESCITALOPRAM OXALATE- ESCITALOPRAM OXALATE TABLET
Contract Pharmacy Services-PA
----------
17.2 FDA-APPROVED MEDICATION GUIDE
MedicationGuide
Escitalopram (EE sye TAL o pram) Tablets, USP
Read the Medication Guide that comes with escitalopram tablets before
you start taking it and each time
you get a refill. There may be new information. This Medication Guide
does not take the place of talking
to your healthcare provider about your medical condition or treatment.
Talk with your healthcare provider
if there is something you do not understand or want to learn more
about.
WhatisthemostimportantinformationIshouldknowaboutescitalopramtablets?
Escitalopram tablets and other antidepressant medicines may cause
serious side effects, including:
1. Suicidal thoughts or actions:
•
Escitalopramtabletsandotherantidepressantmedicinesmayincreasesuicidalthoughtsoractions
in
some children, teenagers, or young adults within the
firstfewmonthsoftreatmentorwhenthedoseischanged.
•
Depression or other serious mental illnesses are the most important
causes of suicidal thoughts or
actions.
•
Watch for these changes and call your healthcare provider right away
if you notice:
•
New or sudden changes in mood, behavior, actions, thoughts, or
feelings, especially if severe.
•
Pay particular attention to such changes when escitalopram tablets are
started or when the dose is
changed.
Keep all follow-up visits with your healthcare provider and call
between visits if you are worried about
symptoms.
Callyourhealthcareproviderrightawayifyouhaveanyofthefollowingsymptoms,
orcall911ifanemergency,
especiallyiftheyarenew, worse, orworryyou:
•
attempts to commit suicide
•
acting on dangerous impulses
•
acting aggressive or violent
•
thoughts about suicide or dying
•
new or worse depression
•
new or worse anxiety or panic attacks
•
feeling agitated, restless, angry or irritable
•
trouble sleeping
•
an increase in activity or talking more than what is normal for you
•
other unusual changes in behavior or mood
Callyourhealthcar
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                ESCITALOPRAM OXALATE- ESCITALOPRAM OXALATE TABLET
CONTRACT PHARMACY SERVICES-PA
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
174 ESCITALOPRAM 20 MG
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
ESCITALOPRAM TABLETS SAFELY AND EFFECTIVELY.
SEE FULL PRESCRIBING INFORMATION FOR ESCITALOPRAM TABLETS.
ESCITALOPRAM TABLETS USP, FOR ORAL USE
INITIAL U.S. APPROVAL: 2002
WARNING: SUICIDALITY AND ANTIDEPRESSANT DRUGS
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
INCREASED RISK OF SUICIDAL THINKING AND BEHAVIOR IN CHILDREN,
ADOLESCENTS AND YOUNG ADULTS TAKING
ANTIDEPRESSANTS FOR MAJOR DEPRESSIVE DISORDER (MDD) AND OTHER
PSYCHIATRIC DISORDERS. ESCITALOPRAM
TABLETS ARE NOT APPROVED FOR USE IN PEDIATRIC PATIENTS LESS THAN 12
YEARS OF AGE (5.1).
RECENT MAJOR CHANGES
Warnings and Precautions (5.9) 07/2014
INDICATIONS AND USAGE
ESCITALOPRAM OXALATE IS A SELECTIVE SEROTONIN REUPTAKE INHIBITOR
(SSRI) INDICATED FOR: (1)
ACUTE AND MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN
ADULTS AND ADOLESCENTS AGED 12
TO 17 YEARS (1.1)
ACUTE TREATMENT OF GENERALIZED ANXIETY DISORDER (GAD) IN ADULTS (1.2)
DOSAGE AND ADMINISTRATION
ESCITALOPRAM TABLETS, USP SHOULD GENERALLY BE ADMINISTERED ONCE DAILY,
MORNING OR EVENING WITH OR
WITHOUT FOOD (2.1, 2.2). (2)
INDICATION
RECOMMENDED DOSE
MDD (2.1)
ADOLESCENTS (2.1)
INITIAL: 10 MG ONCE DAILY
RECOMMENDED: 10 MG ONCE DAILY
MAXIMUM: 20 MG ONCE DAILY
ADULTS (2.1)
INITIAL: 10 MG ONCE DAILY
RECOMMENDED: 10 MG ONCE DAILY
MAXIMUM: 20 MG ONCE DAILY
GAD (2.2)
ADULTS (2.2)
INITIAL: 10 MG ONCE DAILY
RECOMMENDED: 10 MG ONCE DAILY
No additional benefits seen at 20 mg/day dose (2.1).
10 mg/day is the recommended dose for most elderly patients and
patients with hepatic impairment (2.3).
No dosage adjustment for patients with mild or moderate renal
impairment. Use caution in patients with severe renal
impairment (2.3).
Discontinuing escitalopram tablets, USP: A gradual dose reduction is
recommended (2.4).
DOSAGE FORMS AND STRENGTHS
Tablets: 5 mg, 10 mg (scored) and
                                
                                Read the complete document
                                
                            

Search alerts related to this product